Novartis taps Akin Gump to lobby in DC; Google shareholder sues over pharmacy ads;

@FiercePharma: Top drugmakers report payments of $150M to 165K docs so far this year, FT finds. Last full year: $437M. Report | Follow @FiercePharma

> Novartis ($NVS) has hired Akin Gump Strauss Hauer & Feld to lobby in Washington about vaccines after spending $3.6 million on lobbying during the first half of this year. News

> Novartis' ($NVS) Alcon unit in the U.S. sued Apotex to block a generic version of the allergy-fighting nasal spray Patanase. Report

> A Google ($GOOG) shareholder has sued the company and its board, claiming they breached fiduciary duties by running the online pharmacy ads that led to a $500 million settlement with the U.S. government. Story

> After investing $650 million in Vodafone and eyeing pharma investments in U.S. and Europe, Piramal is looking at bidding for India's Future Capital, the financial services arm of Future Group. Article

> In Europe, 95% of doctors go online for professional reasons, and the same percentage uses handheld devices to download apps and access medical information. Item

> BASF plans to increase prices for generic APIs and pharmaceutical excipients by 10% beginning Sept. 1. Report

Biotech News

@FierceBiotech: Actelion drug macitentan flunks PhII but safety data bolsters confidence in blockbuster PhIII. News | Follow @FierceBiotech

@JohnCFierce: The Guardian runs down a litany of biotech failures, challenges and ends on a quick 'up' note regarding collaborations. Piece | Follow @JohnCFierce

@RyanMFierce: New Facebook app "PiggyDemic," from scientists at Tel Aviv University, aims to simulate how viruses spread and mutate. Item | Follow @RyanMFierce

@MaureenFierce: Adimab adds Novo, Biogen Idec to roster of antibody partners. Story | Follow @MaureenFierce

> NuPathe shares in meltdown after FDA rejects migraine patch app. Article

> FDA highlights new tech to monitor trials. News

> New R&D culture at GSK forces a challenging showdown. Story

> Niche cancer drugs highlight the targeting trend in R&D. Item 

> U.K.'s biotech stars may be fading, but new hopefuls. Report

> Bleeding risk spikes for Astellas's PhII anticoagulant. Article 

Biotech Research News

> JHU researchers have a full platelet of blood-clotting research. More

> Researchers find new clues into spread of influenza B. News

> A possible solution found for TTR-related amyloid diseases. Report

> So, a needle-pulling-thread is outdated, doc goes sutureless. Article

> Patient in stem-cell treatment for MS reports improvement. Details

> Researchers dream up a new cause for narcolepsy. Story

Manufacturing News

> Sabotage suspected in U.K. painkiller case. News

> Distributor plans to excise supply chain links. Story

> WHO committee report keeps pharma current. Brief

> Abbott taps manufacturing smarts in Haiti rebuild. Details

> Venus warning letter belies poor 483 response. Article

> Time to put the innovation into manufacturing. More

> U.S. tax reform or not, offshore beckons. Report

And Finally... Scientists found a genetic variant linked to liver cancer in hepatitis C carriers. News

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.